Acrivon Therapeutics, Inc. Stock Price, News & Analysis

Acrivon Therapeutics (Nasdaq: ACRV) said it will present clinical updates in January 2026 covering ACR-368 and ACR-2316 and other AP3 pipeline news.

Key topics include an updated interim ACR-368 readout from the registrational-intent Phase 2b study, an update on a recently initiated tumor biopsy-independent Phase 2b arm, and the company’s planned confirmatory Phase 3 trial. The company will also provide initial Phase 1 data for ACR-2316 (WEE1/PKMYT1 inhibitor) covering safety, dosing regimen, and early clinical activity across AP3-prioritized solid tumors, plus nomination of a new preclinical development candidate with target disclosure for its AP3-driven cell cycle program.

Acrivon Therapeutics (Nasdaq: ACRV) reported third-quarter 2025 results and program updates on Nov 13, 2025. Key highlights include continued advancement of a registrational-intent Phase 2b trial of ACR-368 in recurrent high-grade endometrial cancer, an arm testing ultra-low dose gemcitabine without pre-treatment biopsy, and ongoing dosing in the Phase 1 dose-escalation study of ACR-2316 with reported tumor shrinkage and a confirmed partial response.

Financials: Net loss $18.2M in Q3 2025 versus $22.4M year-ago; R&D $13.6M versus $18.9M; cash and investments $134.4M as of Sept 30, 2025, expected to fund operations into Q2 2027. The company also presented AP3/KaiSR platform and preclinical efficacy data at AACR-NCI-EORTC.

Acrivon Therapeutics (NASDAQ: ACRV) will present three posters at the AACR-NCI-EORTC International Conference (Oct 22-26, 2025) highlighting its Generative Phosphoproteomics AP3 platform and AP3 KaiSR ensemble model.

Preclinical data for ACR-2316 show differentiated and superior pathway effects versus benchmark WEE1 and PKMYT1 inhibitors, with analyses indicating a critical role for PLK1 in ACR-2316’s activity. The company said it will report initial Phase 1 clinical data for ACR-2316 later in 2025 and disclosed clinical activity including a confirmed partial response observed during dose escalation.

Posters will be available on Acrivon’s website shortly after presentation.

Acrivon Therapeutics (Nasdaq: ACRV), a clinical stage biotech company focused on precision medicines, has announced an inducement grant under Nasdaq Rule 5635(c)(4). The company approved stock options for 225,000 shares to one employee, with an exercise price equal to ACRV's closing price on October 1, 2025.

The options will vest 25% after one year from employment start date, followed by 2.083% monthly installments thereafter, contingent on continued employment. The grant was approved by Acrivon's Board as a material inducement to employment.

[]

Acrivon Therapeutics (Nasdaq: ACRV) reported Q2 2025 financial results and business updates, highlighting progress in its clinical-stage assets. The company's lead drug ACR-368 is advancing in a registrational-intent Phase 2 study for endometrial cancer, showing promising responses in patients who progressed after chemotherapy and anti-PD1 therapy. Their second asset, ACR-2316, demonstrated initial clinical activity in Phase 1 trials, including a confirmed partial response in endometrial cancer.

The company reported a net loss of $21.0 million for Q2 2025, with R&D expenses of $16.2 million. Acrivon maintains a strong financial position with $147.6 million in cash and equivalents, expected to fund operations into Q2 2027. Key upcoming milestones include updates on the ACR-368 registrational-intent trial and initial clinical data from ACR-2316's Phase 1 study in H2 2025.

Acrivon Therapeutics (NASDAQ: ACRV) reported its Q1 2025 financial results and key developments. The company highlighted positive data for ACR-368 in endometrial cancer patients, showing a 35% confirmed overall response rate in OncoSignature-positive patients who had received prior anti-PD-1 and platinum-based chemotherapy. Their second clinical asset, ACR-2316, demonstrated promising results with ~25% tumor shrinkage observed in Phase 1 trials. The company appointed Dr. Mansoor Raza Mirza as CMO and reported $164.8 million in cash and equivalents, expected to fund operations into Q2 2027. Financial results showed a net loss of $19.7 million for Q1 2025, compared to $16.5 million in Q1 2024, with R&D expenses increasing to $15.4 million from $11.5 million year-over-year.

Acrivon Therapeutics (NASDAQ: ACRV) announced upcoming data presentation at AACR Annual Meeting 2025 regarding their clinical-stage drug candidate ACR-2316, a selective WEE1/PKMYT1 inhibitor. The Phase 1 trial is progressing ahead of schedule, with three dose-escalation cohorts completed without safety concerns.

Key highlights include:

• ~25% RECIST tumor shrinkage observed at dose level 3
• Drug target engagement confirmed at dose levels 1 and 2
• No dose-limiting toxicities reported
• Currently enrolling dose level 4

The presentation will reveal how ACR-2316, developed using their AP3 Generative Phosphoproteomic platform, induces mitotic and replicative tumor cell death. The drug has shown superior anti-cancer activity in preclinical studies compared to benchmark inhibitors.

Acrivon Therapeutics (Nasdaq: ACRV) has appointed Dr. Mansoor Raza Mirza as Chief Medical Officer, effective April 9, 2025, replacing Jean-Marie Cuillerot. Dr. Mirza, a world-renowned oncology expert specializing in gynecologic malignancies, will lead clinical development including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer and the ACR-2316 Phase 1 study in solid tumors.

Dr. Mirza joins from Copenhagen University National Medical Center, where he served as chief oncologist. He has authored seven articles in the New England Journal of Medicine and led numerous successful trials, including those leading to approvals of Zejula for ovarian cancer and a new frontline therapy for endometrial cancer combining platinum-based chemotherapy with anti-PD-1 checkpoint inhibitor.

Acrivon Therapeutics (NASDAQ: ACRV) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company's ACR-368 showed promising results in endometrial cancer patients, achieving a 35% confirmed overall response rate in OncoSignature-positive patients who had previously progressed on anti-PD-1 and chemotherapy.

Key clinical highlights include a 50% response rate in relapsed patients with duration of response exceeding 10 months, and 33% response rate in refractory patients. The Phase 1 trial of ACR-2316 is ahead of schedule, with initial clinical activity observed. The company has prioritized endometrial cancer development while deprioritizing ovarian and bladder cancer programs.

Financial results show a net loss of $22.8 million for Q4 2024 and $80.6 million for the full year. With $184.6 million in cash and investments as of December 31, 2024, Acrivon expects to fund operations into 2027.